Stay updated with breaking news from Nasdaq Sgmt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Stock analysts at SVB Leerink initiated coverage on shares of Sagimet Biosciences (NASDAQ:SGMT – Get Free Report) in a research report issued to clients and investors on Monday, MarketBeat Ratings reports. The firm set an “outperform” rating and a $26.00 price target on the stock. SVB Leerink’s price target suggests a potential upside of 476.50% […]
Sagimet Biosciences (NASDAQ:SGMT – Free Report) had its price target lifted by The Goldman Sachs Group from $30.00 to $37.00 in a research report sent to investors on Tuesday, Benzinga reports. They currently have a buy rating on the stock. Separately, JMP Securities upped their price target on Sagimet Biosciences from $31.00 to $47.00 and […]
SAN MATEO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (“Sagimet”) (Nasdaq: SGMT), a clinical-stage biopharmaceutical company...
Sagimet Biosciences (NASDAQ:SGMT – Free Report) had its target price lifted by JMP Securities from $31.00 to $47.00 in a research report sent to investors on Monday, Benzinga reports. JMP Securities currently has a market outperform rating on the stock. Sagimet Biosciences Stock Performance Shares of Sagimet Biosciences stock opened at $18.42 on Monday. Sagimet […]
Sagimet Biosciences’ (NASDAQ:SGMT – Get Free Report) lock-up period will expire on Wednesday, January 10th. Sagimet Biosciences had issued 5,312,500 shares in its public offering on July 14th. The total size of the offering was $85,000,000 based on an initial share price of $16.00. After the end of the company’s lock-up period, major shareholders and […]